1. Artemisinin Research Center, and Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China 2. Central People’s Hospital of Zhanjiang, Zhanjiang 524045, China 3. Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China 4. Department of Geriatrics, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People’s Hospital, Shenzhen 518020, China
Malaria is an ancient infectious disease that threatens millions of lives globally even today. The discovery of artemisinin, inspired by traditional Chinese medicine (TCM), has brought in a paradigm shift and been recognized as the “best hope for the treatment of malaria” by World Health Organization. With its high potency and low toxicity, the wide use of artemisinin effectively treats the otherwise drug-resistant parasites and helps many countries, including China, to eventually eradicate malaria. Here, we will first review the initial discovery of artemisinin, an extraordinary journey that was in stark contrast with many drugs in western medicine. We will then discuss how artemisinin and its derivatives could be repurposed to treat cancer, inflammation, immunoregulation-related diseases, and COVID-19. Finally, we will discuss the implications of the “artemisinin story” and how that can better guide the development of TCM today. We believe that artemisinin is just a starting point and TCM will play an even bigger role in healthcare in the 21st century.
YY Tu. Artemisinin—a gift from traditional Chinese medicine to the world (Nobel Lecture). Angew Chem Int Ed Eng, 2016, l55( 35): 10210– 10226
2
World Health Organization. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization, 2020
3
GJ Yoshida. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol, 2017, 10( 1): 67 https://doi.org/10.1186/s13045-017-0436-9
G Li, M Yuan, H Li, C Deng, Q Wang, Y Tang, H Zhang, W Yu, Q Xu, Y Zou, Y Yuan, J Guo, C Jin, X Guan, F Xie, J Song. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Int J Antimicrob Agents, 2021, 57( 1): 106216 https://doi.org/10.1016/j.ijantimicag.2020.106216
7
M Gendrot, I Duflot, M Boxberger, O Delandre, P Jardot, M Le Bideau, J Andreani, I Fonta, J Mosnier, C Rolland, S Hutter, B La Scola, B Pradines. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int J Infect Dis, 2020, 99 : 437– 440 https://doi.org/10.1016/j.ijid.2020.08.032
8
S Krishna, Y Augustin, J Wang, C Xu, HM Staines, H Platteeuw, A Kamarulzaman, A Sall, P Kremsner. Repurposing antimalarials to tackle the COVID-19 pandemic. Trends Parasitol, 2021, 37( 1): 8– 11 https://doi.org/10.1016/j.pt.2020.10.003
9
J Yang, Y He, Y Li, X Zhang, YK Wong, S Shen, T Zhong, J Zhang, Q Liu, J Wang. Advances in the research on the targets of anti-malaria actions of artemisinin. Pharmacol Ther, 2020, 216 : 107697 https://doi.org/10.1016/j.pharmthera.2020.107697
10
J Wang, C Xu, FL Liao, T Jiang, S Krishna, Y Tu. Suboptimal dosing triggers artemisinin partner drug resistance. Lancet Infect Dis, 2019, 19( 11): 1167– 1168 https://doi.org/10.1016/S1473-3099(19)30535-3
11
J Wang, C Xu, FL Liao, T Jiang, S Krishna, Y Tu. A temporizing solution to “artemisinin resistance”. N Engl J Med, 2019, 380( 22): 2087– 2089 https://doi.org/10.1056/NEJMp1901233
12
Strategic Advisory Group on Malaria Eradication. Malaria eradication: benefits, future scenarios and feasibility. A report of the Strategic Advisory Group on Malaria Eradication. Geneva: World Health Organization, 2020
The Nobel Prize. The Nobel Prize in Physiology or Medicine. 2015.
18
World Health Organization. World Health Organization Model List of Essential Medicines. 21st List. Geneva: World Health Organization, 2019
19
RT Eastman, DA Fidock. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol, 2009, 7( 12): 864– 874 https://doi.org/10.1038/nrmicro2239
20
X Sun, P Yan, C Zou, YK Wong, Y Shu, YM Lee, C Zhang, ND Yang, J Wang, J Zhang. Targeting autophagy enhances the anticancer effect of artemisinin and its derivatives. Med Res Rev, 2019, 39( 6): 2172– 2193 https://doi.org/10.1002/med.21580
21
HJ Woerdenbag, TA Moskal, N Pras, TM Malingré, FS el-Feraly, HH Kampinga, AW Konings. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod, 1993, 56( 6): 849– 856 https://doi.org/10.1021/np50096a007
22
HC Lai, NP Singh, T Sasaki. Development of artemisinin compounds for cancer treatment. Invest New Drugs, 2013, 31( 1): 230– 246 https://doi.org/10.1007/s10637-012-9873-z
23
D King, D Yeomanson, HE Bryant. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma. J Pediatr Hematol Oncol, 2015, 37( 4): 245– 251 https://doi.org/10.1097/MPH.0000000000000329
24
J Wang, J Zhang, Y Shi, C Xu, C Zhang, YK Wong, YM Lee, S Krishna, Y He, TK Lim, W Sim, ZC Hua, HM Shen, Q Lin. Mechanistic investigation of the specific anticancer property of artemisinin and its combination with aminolevulinic acid for enhanced anticolorectal cancer activity. ACS Cent Sci, 2017, 3( 7): 743– 750 https://doi.org/10.1021/acscentsci.7b00156
25
ND Yang, SH Tan, S Ng, Y Shi, J Zhou, KSW Tan, WSF Wong, HM Shen. Artesunate induces cell death in human cancer cells via enhancing lysosomal function and lysosomal degradation of ferritin. J Biol Chem, 2014, 289( 48): 33425– 33441 https://doi.org/10.1074/jbc.M114.564567
26
FB Feng, HY Qiu. Effects of artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K/AKT/mTOR signaling pathway in rat models with rheumatoid arthritis. Biomed Pharmacother, 2018, 102 : 1209– 1220 https://doi.org/10.1016/j.biopha.2018.03.142
27
YS Wang, P Yu, Y Wang, J Zhang, W Hang, ZX Yin, G Liu, J Chen, KD Werle, CS Quan, H Gao, Q Zeng, R Cui, J Liang, Q Ding, YL Li, ZX Xu. AMP-activated protein kinase protects against necroptosis via regulation of Keap1-PGAM5 complex. Int J Cardiol, 2018, 259 : 153– 162 https://doi.org/10.1016/j.ijcard.2018.01.036
J Du, T Wang, Y Li, Y Zhou, X Wang, X Yu, X Ren, Y An, Y Wu, W Sun, W Fan, Q Zhu, Y Wang, X Tong. DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin. Free Radic Biol Med, 2019, 131 : 356– 369 https://doi.org/10.1016/j.freeradbiomed.2018.12.011
31
X Zhou, Y Chen, F Wang, H Wu, Y Zhang, J Liu, Y Cai, S Huang, N He, Z Hu, X Jin. Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells. Chem Biol Interact, 2020, 331 : 109273 https://doi.org/10.1016/j.cbi.2020.109273
32
C Cheng, T Wang, Z Song, L Peng, M Gao, O Hermine, S Rousseaux, S Khochbin, JQ Mi, J Wang. Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044. Cancer Med, 2018, 7( 2): 380– 396 https://doi.org/10.1002/cam4.1276
33
A Orlova, C Wagner, Araujo ED de, D Bajusz, HA Neubauer, M Herling, PT Gunning, GM Keserű, R Moriggl. Direct targeting options for STAT3 and STAT5 in cancer. Cancers (Basel), 2019, 11( 12): 1930 https://doi.org/10.3390/cancers11121930
34
X Yan, P Li, Y Zhan, M Qi, J Liu, Z An, W Yang, H Xiao, H Wu, Y Qi, H Shao. Dihydroartemisinin suppresses STAT3 signaling and Mcl-1 and survivin expression to potentiate ABT-263-induced apoptosis in non-small cell lung cancer cells harboring EGFR or RAS mutation. Biochem Pharmacol, 2018, 150 : 72– 85 https://doi.org/10.1016/j.bcp.2018.01.031
35
W Wang, Y Sun, X Li, X Shi, Z Li, X Lu. Dihydroartemisinin prevents distant metastasis of laryngeal carcinoma by inactivating STAT3 in cancer stem cells. Med Sci Monit, 2020, 26 : e922348 https://doi.org/10.12659/MSM.922348
36
M Ilamathi, PC Prabu, KA Ayyappa, V Sivaramakrishnan. Artesunate obliterates experimental hepatocellular carcinoma in rats through suppression of IL-6-JAK-STAT signalling. Biomed Pharmacother, 2016, 82 : 72– 79 https://doi.org/10.1016/j.biopha.2016.04.061
37
M Berköz, F Özkan-Yılmaz, A Özlüer-Hunt, M Krośniak, Ö Türkmen, D Korkmaz, S Keskin. Artesunate inhibits melanoma progression in vitro via suppressing STAT3 signaling pathway. Pharmacol Rep, 2021, 73( 2): 650– 663 https://doi.org/10.1007/s43440-021-00230-6
38
L Zheng, C Wang, T Luo, B Lu, H Ma, Z Zhou, D Zhu, G Chi, P Ge, Y Luo. JNK activation contributes to oxidative stress-induced parthanatos in glioma cells via increase of intracellular ROS production. Mol Neurobiol, 2017, 54( 5): 3492– 3505 https://doi.org/10.1007/s12035-016-9926-y
M Ogata, S Hino, A Saito, K Morikawa, S Kondo, S Kanemoto, T Murakami, M Taniguchi, I Tanii, K Yoshinaga, S Shiosaka, JA Hammarback, F Urano, K Imaizumi. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol, 2006, 26( 24): 9220– 9231 https://doi.org/10.1128/MCB.01453-06
41
Y Wei, S Sinha, B Levine. Dual role of JNK1-mediated phosphorylation of Bcl-2 in autophagy and apoptosis regulation. Autophagy, 2008, 4( 7): 949– 951 https://doi.org/10.4161/auto.6788
42
GD Yao, MY Ge, DQ Li, L Chen, T Hayashi, SI Tashiro, S Onodera, C Guo, SJ Song, T Ikejima. L-A03, a dihydroartemisinin derivative, promotes apoptotic cell death of human breast cancer MCF-7 cells by targeting c-Jun N-terminal kinase. Biomed Pharmacother, 2018, 105 : 320– 325 https://doi.org/10.1016/j.biopha.2018.05.093
AS Baldwin. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest, 2001, 107( 3): 241– 246 https://doi.org/10.1172/JCI11991
45
X Chen, YK Wong, TK Lim, WH Lim, QS Lin, JG Wang, ZC Hua. Artesunate activates the intrinsic apoptosis of HCT116 cells through the suppression of fatty acid synthesis and the NF-κB pathway. Molecules, 2017, 22( 8): 1272 https://doi.org/10.3390/molecules22081272
46
W Hu, SS Chen, JL Zhang, XE Lou, HJ Zhou. Dihydroartemisinin induces autophagy by suppressing NF-κB activation. Cancer Lett, 2014, 343( 2): 239– 248 https://doi.org/10.1016/j.canlet.2013.09.035
47
B Li, S Bu, J Sun, Y Guo, D Lai. Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. Acta Biochim Biophys Sin (Shanghai), 2018, 50( 12): 1227– 1235 https://doi.org/10.1093/abbs/gmy125
48
Y Lin, M Jiang, W Chen, T Zhao, Y Wei. Cancer and ER stress: mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomed Pharmacother, 2019, 118 : 109249 https://doi.org/10.1016/j.biopha.2019.109249
49
R Xiao, C Ding, H Zhu, X Liu, J Gao, Q Liu, D Lu, N Zhang, A Zhang, H Zhou. Suppression of asparagine synthetase enhances the antitumor potency of ART and artemalogue SOMCL-14-221 in non-small cell lung cancer. Cancer Lett, 2020, 475 : 22– 33 https://doi.org/10.1016/j.canlet.2020.01.035
50
TK Våtsveen, MR Myhre, CB Steen, S Wälchli, OC Lingjærde, B Bai, P Dillard, TA Theodossiou, T Holien, A Sundan, EM Inderberg, EB Smeland, JH Myklebust, MP Oksvold. Artesunate shows potent anti-tumor activity in B-cell lymphoma. J Hematol Oncol, 2018, 11( 1): 23 https://doi.org/10.1186/s13045-018-0561-0
51
X Dai, X Zhang, W Chen, Y Chen, Q Zhang, S Mo, J Lu. Dihydroartemisinin: a potential natural anticancer drug. Int J Biol Sci, 2021, 17( 2): 603– 622 https://doi.org/10.7150/ijbs.50364
52
C Shi, H Li, Y Yang, L Hou. Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives. Mediators Inflamm, 2015, 2015 : 435713 https://doi.org/10.1155/2015/435713
53
WL Zhou, JM Wu, QL Wu, JX Wang, Y Zhou, R Zhou, PL He, XY Li, YF Yang, Y Zhang, Y Li, JP Zuo. A novel artemisinin derivative, 3-(12-β-artemisininoxy) phenoxyl succinic acid (SM735), mediates immunosuppressive effects in vitro and in vivo. Acta Pharmacol Sin, 2005, 26( 11): 1352– 1358 https://doi.org/10.1111/j.1745-7254.2005.00232.x
54
ZS Yang, JX Wang, Y Zhou, JP Zuo, Y Li. Synthesis and immunosuppressive activity of new artemisinin derivatives. Part 2: 2-[12(β or α)-dihydroartemisinoxymethyl(or 1′-ethyl)]phenoxyl propionic acids and esters. Bioorg Med Chem, 2006, 14( 23): 8043– 8049 https://doi.org/10.1016/j.bmc.2006.07.038
55
JX Zhang, JX Wang, Y Zhang, JP Zuo, JM Wu, Y Sui, Y Li . Synthesis and immunosuppressive activity of new artemisinin derivatives containing polyethylene glycol group. Acta Pharmaceutica Sinica (Yao Xue Xue Bao) 2006; 41(1): 65–70 (in Chinese)
pmid: 16683530
56
LF Hou, SJ He, JX Wang, Y Yang, FH Zhu, Y Zhou, PL He, Y Zhang, YF Yang, Y Li, W Tang, JP Zuo. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int Immunopharmacol, 2009, 9( 13–14): 1509– 1517 https://doi.org/10.1016/j.intimp.2009.09.003
57
L Hou, KE Block, H Huang. Artesunate abolishes germinal center B cells and inhibits autoimmune arthritis. PLoS One, 2014, 9( 8): e104762 https://doi.org/10.1371/journal.pone.0104762
58
Y He, J Fan, H Lin, X Yang, Y Ye, L Liang, Z Zhan, X Dong, L Sun, H Xu. The anti-malaria agent artesunate inhibits expression of vascular endothelial growth factor and hypoxia-inducible factor-1α in human rheumatoid arthritis fibroblast-like synoviocyte. Rheumatol Int, 2011, 31( 1): 53– 60 https://doi.org/10.1007/s00296-009-1218-7
59
LF Hou, SJ He, X Li, Y Yang, PL He, Y Zhou, FH Zhu, YF Yang, Y Li, W Tang, JP Zuo. Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. Arthritis Rheum, 2011, 63( 8): 2445– 2455 https://doi.org/10.1002/art.30392
60
WD Li, YJ Dong, YY Tu, ZB Lin. Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation. Int Immunopharmacol, 2006, 6( 8): 1243– 1250 https://doi.org/10.1016/j.intimp.2006.03.004
61
Y Tang, J Liu, D Zhang, Z Xu, J Ji, C Wen. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol, 2020, 11 : 1708 https://doi.org/10.3389/fimmu.2020.01708
62
M Gendrot, I Duflot, M Boxberger, O Delandre, P Jardot, M Le Bideau, J Andreani, I Fonta, J Mosnier, C Rolland, S Hutter, B La Scola, B Pradines. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: in vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int J Infect Dis, 2020, 99 : 437– 440 https://doi.org/10.1016/j.ijid.2020.08.032
63
G Li, M Yuan, H Li, C Deng, Q Wang, Y Tang, H Zhang, W Yu, Q Xu, Y Zou, Y Yuan, J Guo, C Jin, X Guan, F Xie, J Song. Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. Int J Antimicrob Agents, 2021, 57( 1): 106216 https://doi.org/10.1016/j.ijantimicag.2020.106216
64
S Krishna, Y Augustin, J Wang, C Xu, HM Staines, H Platteeuw, A Kamarulzaman, A Sall, P Kremsner. Repurposing antimalarials to tackle the COVID-19 pandemic. Trends Parasitol, 2021, 37( 1): 8– 11 https://doi.org/10.1016/j.pt.2020.10.003
65
K Chen, H Hua, Z Zhu, T Wu, Z Jia, Q Liu. Artemisinin and dihydroartemisinin promote β-cell apoptosis induced by palmitate via enhancing ER stress. Apoptosis, 2020, 25( 3–4): 192– 204 https://doi.org/10.1007/s10495-019-01587-z
66
X Xue, Z Dong, Y Deng, S Yin, P Wang, Y Liao, G Hu, Y Chen. Dihydroartemisinin alleviates atopic dermatitis in mice by inhibiting mast cell infiltration. J South Med Univ (Nan Fang Yi Ke Da Xue Xue Bao) 2020; 40(10): 1480–1487 (in Chinese)
pmid: 33118501
67
X Nong, G Rajbanshi, L Chen, J Li, Z Li, T Liu, S Chen, G Wei, J Li. Effect of artesunate and relation with TGF-β1 and SMAD3 signaling on experimental hypertrophic scar model in rabbit ear. Arch Dermatol Res, 2019, 311( 10): 761– 772 https://doi.org/10.1007/s00403-019-01960-7
68
FM Yang, D Fan, XQ Yang, FH Zhu, MJ Shao, Q Li, YT Liu, ZM Lin, SQ Cao, W Tang, SJ He, JP Zuo. The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-κB/NLRP3 signaling. Acta Pharmacol Sin, 2021, 42( 4): 593– 603 https://doi.org/10.1038/s41401-020-0484-5
69
J Liu, E Manheimer, Y Shi, C Gluud. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. J Altern Complement Med, 2004, 10( 6): 1041– 1051 https://doi.org/10.1089/acm.2004.10.1041
70
World Health Organization. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine. Geneva: World Health Organization, 2004
71
National Administration of Traditional Chinese Medicine . The Traditional Chinese Medicine Prevention Program of Influenza A (H1N1) (2009). National Administration of Traditional Chinese Medicine, 2009 (in Chinese)
72
H Luo, QL Tang, YX Shang, SB Liang, M Yang, N Robinson, JP Liu. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs.. Chin J Integr Med, 2020, 26( 4): 243– 250 https://doi.org/10.1007/s11655-020-3192-6